Cancer Drugs' hidden cost: tracking vision damage in melanoma patients
NCT ID NCT07431489
Summary
This study looked at how certain melanoma cancer drugs affect patients' eyes and vision. Researchers followed 30 adults taking BRAF/MEK inhibitor combinations to understand how often these drugs cause retinal changes called MEKAR. Participants received regular eye exams before, during, and after treatment to track any vision problems or eye damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
Conditions
Explore the condition pages connected to this study.